ArticleEuropean journal of pediatrics2025
Clinical characteristics of 50 hepatocellular adenoma patients among 164 cases of glycogen storage disease type Ia.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genotype-phenotype spectrum and clinical outcomes of glycogen storage disease type I: A 15-year experience at Vietnam National Children's Hospital.Molecular genetics and metabolism reports · 2026Article
- Successful surgical management of multiple hepatocellular adenomas in a young female patient with glycogen storage disease type Ia: a case report.Journal of medical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hepatocellular adenoma (HCA) can occur in patients with glycogen storage disease type Ia (GSDIa), which is caused by mutations in the glucose-6-phosphatase gene (G6PC). Studies on HCA in GSDIa patients are limited and show variable results. Larger cohorts of GSDIa patients with HCA should be investigated. In this study, we examined the clinical characteristics and G6PC genotypes of 50 patients with HCA among 164 GSDIa cases. The incidence of HCA in GSDIa patients was 30.5% and increased with age. The mean age of HCA onset was 16.5 ± 4.4 years. The median age of GSDIa patients with HCA who received uncooked cornstarch treatment was significantly older than that of patients without HCA (14 years (11, 16.5) vs. 3 years (1, 9), p = 0.000). Median plasma triglyceride levels significantly decreased after treatment with uncooked cornstarch (5.36 mmol/L (3.44, 8.73) vs. 8.35 mmol/L (5.44, 13.27), p = 0.004). The most common G6PC genotype in GSDIa patients was [c.648G > T] + [c.648G > T]. The incidence of the G6PC [c.648G > T] + [c.248G > A] genotype was significantly lower in GSDIa patients with HCA compared to that in GSDIa patients without HCA (2.0% (1/49) vs. 14.7% (16/109), p = 0.018). Some HCAs with small diameters may temporarily disappear. Conclusion: Special attention should be paid to the occurrence of HCAs in GSDIa patients, particularly during adolescence. Earlier initiation of uncooked cornstarch treatment may reduce the incidence or delay the onset of HCAs by lowering triglyceride levels. Small and stable HCAs can be closely followed up since they may disappear temporarily.
Indexed as
Identifiers
40586975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.